Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

ClinicalTrials.gov ID: NCT05445778

Public ClinicalTrials.gov record NCT05445778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Study identification

NCT ID
NCT05445778
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
520 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2023 (Actual)
Primary completion
Apr 2027 (Estimated)
Completion
May 2032 (Estimated)
Last update posted
Jun 2, 2026

2023 – 2032

United States locations

U.S. sites
74
U.S. states
31
U.S. cities
65
Facility City State ZIP Site status
Usa Mitchell Cancer Institute /ID# 269661 Mobile Alabama 36604 —
Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 Phoenix Arizona 85016 —
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 Irvine California 92618 —
Moores Cancer Center at UC San Diego /ID# 269564 La Jolla California 92093 —
Kaiser Permanente - Los Angeles Medical Center /ID# 269541 Los Angeles California 90027 —
University Of California Irvine Medical Center /ID# 269572 Orange California 92868 —
Stanford Women'S Cancer Center /ID# 269552 Palo Alto California 94304 —
Kaiser Permanente - Riverside Medical Center /ID# 269539 Riverside California 92505 —
Kaiser Permanente Zion Medical Center /ID# 269537 San Diego California 92120 —
Kaiser Permanente - San Diego Medical Center /ID# 269540 San Diego California 92123 —
Kaiser Permanente - San Marcos Medical Offices /ID# 269542 San Marcos California 92069 —
Olive View-Ucla Medical Center /ID# 269584 Sylmar California 91342 —
John Muir Health - Walnut Creek Medical Center /ID# 269575 Walnut Creek California 94598 —
Broward General Medical Center /ID# 269577 Fort Lauderdale Florida 33316 —
Regional Cancer Center /ID# 269558 Fort Myers Florida 33905 —
Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560 Jacksonville Florida 32207 —
Mount Sinai Medical Center /ID# 269582 Miami Florida 33140 —
Sarasota Memorial Hospital /ID# 269526 Sarasota Florida 34239 —
Northside Hospital /ID# 269660 Atlanta Georgia 30342 —
Rush University Medical Center /ID# 269583 Chicago Illinois 60612 —
University of Chicago Medical Center /ID# 269546 Chicago Illinois 60637 —
Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 269110 Indianapolis Indiana 46202-5116 —
St. Vincent Indianapolis Hospital /ID# 269107 Indianapolis Indiana 46260 —
University of Iowa /ID# 269566 Iowa City Iowa 52242 —
The University of Kansas Cancer Center - Westwood /ID# 269106 Westwood Kansas 66205 —
Baptist Health Lexington /ID# 269568 Lexington Kentucky 40503 —
University of Kentucky Chandler Medical Center. /ID# 269536 Lexington Kentucky 40536 —
Louisiana State University Health Sciences Center - New Orleans /ID# 269559 New Orleans Louisiana 70112 —
Ochsner Medical Center - Jefferson Highway /ID# 269530 New Orleans Louisiana 70121 —
Maine Medical Center - Scarborough Campus /ID# 269555 Scarborough Maine 04074 —
Johns Hopkins Hospital /ID# 269579 Baltimore Maryland 21287 —
Sinai Hospital Of Baltimore /ID# 269567 Manchester Maryland 21215 —
GBMC Cancer Center /ID# 269561 Towson Maryland 21204-6831 —
Tufts Medical Center /ID# 269547 Boston Massachusetts 02111-1552 —
Baystate Medical Center /ID# 269544 Springfield Massachusetts 01199 —
Corewell Health /ID# 269562 Grand Rapids Michigan 49503 —
Minnesota Oncology - Coon Rapids Clinic /ID# 269550 Coon Rapids Minnesota 55433 —
Nebraska Methodist Hospital /ID# 269580 Omaha Nebraska 68114 —
The Center Of Hope /ID# 269528 Reno Nevada 89511 —
Dartmouth-Hitchcock Medical Center /ID# 269576 Lebanon New Hampshire 03756 —
John Theurer Cancer Center /ID# 269109 Hackensack New Jersey 07601 —
The Valley Hospital /ID# 269548 Paramus New Jersey 07652 —
Holy Name Medical Center /ID# 269543 Teaneck New Jersey 07666 —
New York Oncology Hematology - Albany Cancer Center /ID# 269565 Albany New York 12206-5013 —
Women'S Cancer Care Associates /ID# 269553 Albany New York 12208 —
Northwell Health Center for Advanced Medicine. /ID# 269108 Lake Success New York 11042 —
Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates - Mineola /ID# 269534 Mineola New York 11501 —
NYU Laura and Isaac Perlmutter Cancer Center /ID# 269556 New York New York 10016 —
Icahn School of Medicine at Mount Sinai /ID# 269529 New York New York 10029 —
University of North Carolina at Chapel Hill /ID# 269563 Chapel Hill North Carolina 27514 —
Duke Cancer Institute /ID# 269557 Durham North Carolina 27710 —
University of Cincinnati /ID# 269578 Cincinnati Ohio 45267-2827 —
Jamescare Gynecologic Oncology At Mill Run /ID# 269105 Hilliard Ohio 43026 —
Kettering Medical Center /ID# 269585 Kettering Ohio 45429 —
OU Health - Stephenson Cancer Center /ID# 269525 Oklahoma City Oklahoma 73104 —
Oklahoma Cancer Specialists and Research Institute /ID# 269527 Tulsa Oklahoma 74146 —
Willamette Valley Cancer Institute and Research Center /ID# 269988 Eugene Oregon 97401 —
Compass Oncology - Rose Quarter /ID# 270131 Portland Oregon 97227 —
Oregon Health and Science University /ID# 269581 Portland Oregon 97239 —
University Of Pittsburgh Medical Center Magee - Womens Hospital /ID# 269659 Pittsburgh Pennsylvania 15213 —
Allegheny Health Network West Penn Hospital /ID# 269551 Pittsburgh Pennsylvania 15244 —
Asplundh Cancer Pavilion /ID# 269574 Willow Grove Pennsylvania 19090 —
Sanford Cancer Center /ID# 269535 Sioux Falls South Dakota 57104 —
West Cancer Center and Research Institute - Germantown /ID# 269569 Germantown Tennessee 38138 —
Texas Oncology - Austin Central /ID# 269531 Austin Texas 78731 —
Texas Oncology - Bedford /ID# 269571 Bedford Texas 76022 —
Texas Oncology - Methodist Dallas Cancer Center /ID# 269554 Dallas Texas 75203 —
Texas Oncology - Fort Worth Cancer Center /ID# 269532 Fort Worth Texas 76104 —
US Oncology Research Investigational Products Center /ID# 278746 Irving Texas 75063 —
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 269549 San Antonio Texas 78240 —
University of Virginia Health System /ID# 269545 Charlottesville Virginia 22908-0816 —
Virginia Oncology Associates - Norfolk (Lake Wright) /ID# 269533 Norfolk Virginia 23502 —
VCU Health Adult Outpatient Pavillion /ID# 269570 Richmond Virginia 23219 —
Swedish Cancer Institute /ID# 269538 Seattle Washington 98104-3588 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 190 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05445778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 2, 2026 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05445778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →